SAB Biotherapeutics Inc (SABS) — Capital Reinvestment Ratio

Latest as of December 2022: 0.54x

SAB Biotherapeutics Inc (SABS) has a Capital Reinvestment Ratio of 0.54x as of December 2022, meaning it reinvests 1% of its operating cash flow ($216.72K) in capital expenditures ($117.75K). See SAB Biotherapeutics Inc net asset quality index to measure how much of total assets are equity-financed.

Capital Reinvestment Ratio

0.54x
Capex / Operating Cash Flow

Operating Cash Flow

$216.72K
USD

Capital Expenditures

$117.75K
USD

Data as of

Dec 2022
Most recent filing

SAB Biotherapeutics Inc Capital Reinvestment Ratio (2020–2021)

This chart tracks SAB Biotherapeutics Inc's Capital Reinvestment Ratio across 2 annual periods. Check how aggressively does SAB Biotherapeutics Inc reinvest cash to assess the company's total reinvestment commitment from operating cash flow.

Annual Capital Reinvestment Ratio for SAB Biotherapeutics Inc (2020–2021)

Year-by-year Capital Reinvestment Ratio for SAB Biotherapeutics Inc from 2020 to 2021. For live market cap and broader valuation context, see SAB Biotherapeutics Inc (SABS) market capitalisation.

Year Reinvestment Ratio Operating CF (USD) Capital Expenditures YoY Change
2021 5.51x $1.99 Million $10.94 Million ▲ +332.8%
2020 1.27x $10.00 Million $12.73 Million
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow